``By the time definitive trials of Vytorin are done in 2012, the drug will be dead,'' said Fayez Shamoon, director of cardiology at Seton Hall University in Newark, New Jersey. ``I don't feel I have the right to put my patient on Vytorin'' because if something goes wrong or the patient has a complication, ``he's going to come after the physician, Shamoon said. ``We are really under pressure not to use the drug again.''
Bloomberg
No comments:
Post a Comment